Benralizumab: Phase III started

AstraZeneca disclosed in its 2Q14 earnings that it began the double-blind, double-dummy, placebo-controlled, international Phase III Galathea trial to evaluate 2 doses of subcutaneous benralizumab in about 3,788 COPD patients with moderate to very severe COPD who are receiving standard of care therapies and have a history of exacerbations. The company also began the Phase III Terranova trial in COPD patients. The trials are part of the Phase III Voyager program. ...